Biotech Values

[iwfal]

CLDX -

To me, the result is still trending toward HG regardless of TN status

In the HG without TN status the ORR comparison is 28% vs 20% with a p value near 1.0. I'd suggest it is a stretch to call that a trend. And the PFS data, being both more perceptive and of more clinical and regulatory importance, is HR is about 0.85 with a p value near 1.0. Again, hard to claim even a trend for HG without TN status. So unless they have some amazing OS data in that subgroup I would hope that they kill it.